Intetumumab

**Semantic type:** Amino Acid, Peptide, or Protein|Immunologic Factor|Pharmacologic Substance

**Definition:** A pan alpha-v human monoclonal antibody that recognizes alpha-v beta-1, alpha-v beta-3, alpha-v beta-5, and alpha-v beta-6 integrins with antiangiogenic and antitumor activities. Intetumumab competitively binds to and blocks both alpha-v beta-3 and alpha-v beta-5 integrins, resulting in inhibition of integrin-mediated tumor angiogenesis and tumor growth. Integrins facilitate the adhesion of stimulated endothelial cells to the extracellular matrix (ECM); trigger the secretion of ECM-rearranging proteases; and propagate signaling events that promote the survival and differentiation of cells in newly formed vasculature.

**Synonyms:** - CNTO 095 - CNTO-95 - Human Anti-Alpha-5 Integrin Monoclonal Antibody - Human Monoclonal CNTO 95 gamma1 heavy chain (222-215')-disulfide with Human Monoclonal CNTO 95 kappa light chain dimer (228-228'':231-231'')-bisdisulfide - INTETUMUMAB - Immunoglobulin G1, anti-(human integrin alpha-V (vitronectin receptor subunit alpha or CD51))